Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncology products addressing clear unmet pediatric and adult medical needs. With the right partnerships and collaborations, we envision changing the course of cancer care and its outcomes.
We're tracking Y-mAbs Therapeutics, Inc.'s market expansion
6 signals in the last 90 days.
How Y-mAbs Therapeutics, Inc.'s international expansion compares to its competitors
Y-mAbs Therapeutics, Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Y-mAbs Therapeutics, Inc.You | 0 | 0 | — | 0 | 0 |
Senior Director / Director, Medical (Oncology)
View postingCopenhagen, Capital Region of Denmark, Denmark · 11mo ago
Senior Manager / Associate Director, GMP Global QA
View postingHørsholm, Capital Region of Denmark, Denmark · 11mo ago
Finance Manager
View postingHørsholm, Capital Region of Denmark, Denmark · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Telix Pharmaceuticals appoints David Gill as Non-Executive Director effective May 11, 2026, with plans for him to become Chair. Gill brings 35+ years of life sciences experience.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Y-mAbs Therapeutics, Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
